DENVER, Oct. 6, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that SUNY Upstate Cancer Center in Syracuse, New York has selected MRIdian MRI-Guided Radiation Therapy System and will be the first in Upstate New York to offer the precision of MRIdian's advanced MRI-guided radiation therapy to cancer patients throughout the region for pancreas, prostate, lung, liver, breast, and oligometastatic cancers.
SUNY Upstate Cancer Center is the region's most comprehensive resource for cancer care and offers the most advanced outpatient treatment, clinical research studies, and support services all in one convenient location. The Upstate Cancer Center is the only hospital in Central New York to use a team approach, combining the expertise of surgeons, medical oncologists, and radiation oncologists in a multidisciplinary approach to help patients fighting cancer.
"Every patient deserves personalized cancer care," said Paul Ziegler, Chief Commercial Officer of ViewRay. "We are honored to be working with the team from SUNY Upstate Cancer Center to as they bring the clinical benefits of MRIdian radiation therapy to the people of the Upstate New York region. We believe MRIdian is an excellent fit for SUNY's multidisciplinary approach and will allow radiation oncologists, medical oncologists, and surgeons to tailor treatment for their cancer patients."
Ad Statistics
Times Displayed: 75267
Times Visited: 5317 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
The MRIdian system provides oncologists outstanding anatomical visualization through diagnostic-quality MR images and the ability to adapt a radiation therapy plan to the targeted cancer with the patient on the table. This combination allows physicians to define tight treatment margins to avoid unnecessary radiation exposure of vulnerable organs-at-risk and healthy tissue and allows the delivery of ablative radiation doses in five or fewer treatment sessions, without relying on implanted markers. By providing real-time continuous tracking of the target and organs-at-risk, MRIdian enables automatic gating of the radiation beam if the target moves outside the user-defined margins. This allows for delivery of the prescribed dose to the target, while sparing surrounding healthy tissue and critical structures, which results in minimizing toxicities typically associated with conventional radiation therapy.
To date, over 25,000 patients have been treated with MRIdian. Currently, 54 MRIdian systems are installed at hospitals around the world where they are used to treat a wide variety of solid tumors and are the focus of numerous ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts, and presentations.
About ViewRay
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures, and markets the MRIdian® MRI-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
SOURCE ViewRay, Inc.